Different durations of adjuvant anastrozole therapy after 2 to 3 years tamoxifen therapy in breast cancer - DATA
Study identifier:D5392NL003
ClinicalTrials.gov identifier:NCT00301457
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A prospective randomised, open, multicentre, phase III study to assess different durations of anastrozole therapy after 2 to 3 years tamoxifen as adjuvant therapy in postmenopausal women with breast cancer.
Medical condition
Breast Cancer
Phase
Phase 3
Healthy volunteers
No
Study drug
Anastrozole
Sex
Female
Actual Enrollment
1914
Study type
Interventional
Age
45 Years - 99 Years
Date
Study Start Date: 01 Jun 2006
Primary Completion Date: 01 Apr 2016
Study Completion Date: 01 Apr 2016
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 May 2016 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 6 years adjuvant anastrozole therapy | Drug: Anastrozole 1 mg once daily oral dose Other Name: ARIMIDEX Other Name: ZD1033 |
| Experimental: 2 3 years adjuvant anastrozole therapy | Drug: Anastrozole 1 mg once daily oral dose Other Name: ARIMIDEX Other Name: ZD1033 |
Contacts
Investigators
Principal Investigator
AstraZeneca Netherlands Medical Director
AstraZeneca
